Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Boston Scientific (BSX) to $80 from $96 and keeps an Outperform rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific Investors File Lawsuit Over Alleged Misleading Statements About Electrophysiology Business Growth
- AI Models Turn More Positive on Boston Scientific, But Weak Technicals Temper Enthusiasm
- FTC issued Second Request to Penumbra, Boston Scientific over merger review
- Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
- Boston Scientific upside scenario unlikely after data, says Wells Fargo